NCT02107703
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with clinical evidence or history of central nervous system metastasis or leptomeningeal disease; Patients who have received prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib)
https://ClinicalTrials.gov/show/NCT02107703